Carol Kooistra, MD
Neurology · Spartanburg, SCNPI 1598741837
Payments from drug & device makers
Across 1,557 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$2K
- UCB, Inc.$2K
- EMD Serono, Inc.$2K
- Biogen$1K
- Novartis$1K
- plus $19K from 54 others
What the payments were for
- Speaking & faculty fees$1350%
- Travel & lodging$1,0043%
- Food & beverage$27,22794%
- Education$5912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,239
- UPLIZNA$173
- Austedo XR$123
- PANZYGA$113
- ULTOMIRIS$100
How this compares
$28,957 in reported general payments places this provider in the 80th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 81 | $792,035 |
| Kesimpta PenOfatumumab | 58 | $505,624 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 27 | $277,111 |
| VumerityDiroximel Fumarate | 24 | $206,502 |
| FingolimodFingolimod Hcl | 23 | $104,300 |
| RemicadeInfliximab | 15 | $90,214 |
| Aimovig AutoinjectorErenumab-Aooe | 110 | $84,804 |
| Nurtec OdtRimegepant Sulfate | 41 | $62,768 |
| QuliptaAtogepant | 48 | $56,449 |
| NuedextaDextromethorphan Hbr/Quinidine | 34 | $55,882 |
| GlatopaGlatiramer Acetate | 14 | $44,412 |
| UbrelvyUbrogepant | 33 | $40,450 |
| Emgality PenGalcanezumab-Gnlm | 40 | $35,377 |
| Dalfampridine ErDalfampridine | 63 | $29,921 |
| KeppraLevetiracetam | 14 | $22,387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $833 | $792,03581 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Trintellix | $319 | $291,18651 claims |
| BiogenVumerity | $1,478 | $206,50224 claims |
| AbbVieQulipta, Ubrelvy | $2,116 | $96,89981 claims |
| Johnson & JohnsonRemicade | $268 | $90,21415 claims |
| PfizerNurtec Odt, Eliquis | $1,065 | $84,67868 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $327 | $55,88234 claims |
| Eisai Inc.Fycompa | $835 | $21,79818 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $91 | $13,18413 claims |
| AstraZenecaBrilinta | $1,092 | $7,95219 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $150 | $5,66132 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $1,759 | $3,85517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 270 neurology providers in South Carolina.
Other neurology in Spartanburg
- Juliette SaadSpartanburg$445K
- Bogdan GheorghiuSpartanburg$106K
- Mary HughesGreenville$6.3M
- William McElveenColumbia$3.7M
- Robert CarlileSummerville$2.3M
- Andrew KeeganCharleston$2.2M
- Paul MazzeoPort Royal$1.7M
- Vanessa HinsonCharleston$1.5M
- David SticklerNorth Charleston$1.2M
- Katherine RuzhanskyCharleston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.